Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
09. Mai 2022 08:30 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31,...
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
31. März 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended...
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
15. März 2022 17:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
17. Februar 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to...
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
25. Januar 2022 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
22. November 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
Catalyst Biosciences Announces Change in Corporate Strategy
12. November 2021 07:00 ET
|
Catalyst Biosciences, Inc.
Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
29. Oktober 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two...
Catalyst Biosciences Announces Chief Financial Officer Transition
13. Oktober 2021 16:05 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal...
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
28. September 2021 16:01 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...